EVGN
Evogene
NASDAQ: EVGN · HEALTHCARE · BIOTECHNOLOGY
$0.78
+2.88% today
Updated 2026-04-30
Market cap
$9.54M
P/E ratio
—
P/S ratio
2.48x
EPS (TTM)
$-1.70
Dividend yield
—
52W range
$1 – $2
Volume
0.1M
WallStSmart proprietary scores
16
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+4.5
Quality
C2.0
Profitability
F6.7
Valuation
B2/9
Piotroski F-Score
Weak
-10.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$2.25
+188.46%
12-Month target
—
—
Intrinsic (DCF)
$2.27
Margin of safety
+55.07%
0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ 55.07% below intrinsic value
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -10.24 — distress zone
- Thin margins at -220.20%
- Negative free cash flow $-3.02M
- Revenue declining -80.50% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.68M | $5.64M | $8.51M | $3.85M | $3.85M |
| Net income | $-26.64M | $-23.88M | $-16.48M | $-8.48M | $-5.31M |
| EPS | — | — | — | — | $-1.70 |
| Free cash flow | $-24.85M | $-22.36M | $-20.33M | $-13.64M | $-3.02M |
| Profit margin | -1,590.33% | -423.39% | -193.69% | -220.22% | -220.20% |
Peer comparison
Smart narrative
Evogene trades at $0.78. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -10.24, it sits in the distress. TTM revenue stands at $3.85M. with profit margins at -220.20%. Our DCF model estimates intrinsic value at $2.27.
Frequently asked questions
What is Evogene's stock price?
Evogene (EVGN) trades at $0.78.
Is Evogene overvalued?
Smart Value Score 16/100 (Grade F, Strong Sell). DCF value $2.27.
What is the price target of Evogene (EVGN)?
The analyst target price is $2.25, representing +188.5% upside from the current price of $0.78.
What is the intrinsic value of Evogene (EVGN)?
Based on our DCF model, intrinsic value is $2.27, a +55.1% margin of safety versus $0.78.
What is Evogene's revenue?
TTM revenue is $3.85M.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
-10.24 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.48x
ROE-100.70%
Beta0.95
50D MA$0.83
200D MA$1.09
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—